Biodrugs

Papers
(The TQCC of Biodrugs is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond371
Comparative Safety Profiles of Oncology Biosimilars: A Systematic Review and Network Meta-analysis337
Emerging Therapy in Osteoarthritis: Mesenchymal Stem Cells, Secretomes, and Using Hydrogels to Enhance Efficacy140
Recurring Fatigue After Biologic Administration: Patient-Reported Data from the Dutch Biologic Monitor116
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis101
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery100
The Path to Accessible Care: Development and Impact of Eculizumab Biosimilars for Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome81
New and Emerging Biological Therapies for Myasthenia Gravis: A Focussed Review for Clinical Decision-Making78
Correction: Mirikizumab as Induction and Maintenance Therapy in Chinese Patients with Ulcerative Colitis: A Subpopulation Analysis of the Randomized, Global Phase 3 LUCENT-1 and LUCENT-2 Trials68
Why Product Drift Is Not an Issue for Biosimilars/Biologics: Start the Same, Stay the Same63
Acknowledgement to Referees56
Localised Delivery of Macromolecules to the Large Intestine: Translation to Clinical Trials47
In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart44
CAR-T Cells and the Kidney: Insights from the WHO Safety Database43
Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009–202240
Demand- Versus Supply-Side Policies in Market Penetration of Biosimilars: Which is More Effective?39
Correction: Real-World Use of Dostarlimab Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer: A Nationwide Cohort Study in France38
Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells38
The Present and Future of Monoclonal Antibody Therapies for Multiple Sclerosis36
Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study36
Gene Therapy Strategies for Uveal Melanoma: Adeno-associated Virus Delivery Challenges and Translational Opportunities35
Correction: Dystrophin- and Utrophin-Based Therapeutic Approaches for Treatment of Duchenne Muscular Dystrophy: A Comparative Review34
Progress and Challenges in the Treatment of Fabry Disease34
Characterization of Biosimilar Monoclonal Antibodies and Their Reference Products Approved in Japan to Reveal the Quality Characteristics in Post-approval Phase34
Malaria Vaccines: Progress to Date32
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer31
Do the Outcomes of Clinical Efficacy Trials Matter in Regulatory Decision-Making for Biosimilars?30
Interleukin-23 Inhibitors in Inflammatory Bowel Disease29
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects29
Acknowledgement to Referees28
Biochemical Amenability in Fabry Patients Under Chaperone Therapy—How and When to Test?28
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case Series28
Advanced Combination Therapy in Inflammatory Bowel Disease: What Does the Future Hold?27
Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options27
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network27
Targeted Gene Insertion: The Cutting Edge of CRISPR Drug Development with Hemophilia as a Highlight25
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment25
Defining a Framework for Sustainable Global Biosimilars Markets Using Findings from a Targeted Literature Review25
Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study24
Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics22
Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects21
Recombinant Protein Drugs: A 2025 Update21
Interleukin-17 Inhibitors in the Treatment of Hidradenitis Suppurativa21
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Stu20
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis20
Exploring the Use of Monoclonal Antibodies and Antiviral Therapies for Early Treatment of COVID-19 Outpatients in a Real-World Setting: A Nationwide Study from England and Italy20
TL1A Inhibition in Inflammatory Bowel Disease: A Pipeline Review20
The Use of Biologics for Thyroid Eye Disease19
Next-Generation Anti-TNFα Agents: The Example of Ozoralizumab19
Extracellular Vesicles and Immune Activation in Solid Organ Transplantation: The Impact of Immunosuppression18
Acute Kidney Injury from Intravitreal Anti-vascular Endothelial Growth Factor Drugs: A Systematic Review and Meta-analysis of Randomized Controlled Trials18
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine17
Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database17
Use of Semaglutide (Wegovy) in Adults in France: A Nationwide Drug Utilization Study17
Impact of Early Access Reform on Oncology Innovation in France: Approvals, Patients, and Costs16
Recurrent Clostridioides difficile Infection: Current Clinical Management and Microbiome-Based Therapies16
Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases16
Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria16
Biosimilar Uptake in Spain from 2016 to 2023: Analysis Based on Official Data Collection16
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease15
Targeting the Inside of Cells with Biologicals: Toxin Routes in a Therapeutic Context15
Patients’ Perceptions of Biosimilars: A Systematic Review14
Advances of Antimicrobial Peptides in the Treatment of Multidrug-Resistant Bacteria14
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing14
CRISPR-Cas System: A New Dawn to Combat Antibiotic Resistance14
0.34143686294556